The most common contraindications relevant to lung cancer therapy have been classic activating mutations in EGFR, where prior TKI use has been linked to a long-lasting increased risk of severe and almost always fatal pneumonitis, requiring permanent discontinuation of immunotherapy, with the risk increasing with additionally therapeutic modalities such as radiotherapy [80,81]). This evidence concerns the gene EGFR and lung carcinoma.